Novo Nordisk A/S and Microsoft Inc have entered a partnership to investigate how artificial intelligence can be applied to drug discovery and development. The collaboration draws on Novo’s experience in pharma R&D and Microsoft’s computational services and AI expertise to develop a series of case studies showing applications of the new technologies. Financial terms of the agreement were not disclosed.
The European Medicines Agency has recommended approval of a bivalent vaccine to protect against two sub-variants of the SARS-CoV-2 virus. The authorisation is for an updated booster shot developed by Pfizer Inc and BioNTech SE to protect people against the omicron subvariants BA.4 and BA.5 in addition to the original strain of SARS-CoV-2. The new vaccine is to be used in people aged 12 years and older who have received at least a primary course of vaccination to prevent Covid-19.
Novo Nordisk A/S, whose main therapeutic focus is diabetes, has expanded its presence in the field of rare blood disorders with an agreement to acquire Forma Therapeutics Holdings Inc of the US. Forma’s lead product etavopivat is a small molecule allosteric activator of the red blood cell isoform of pyruvate kinase. It is being developed to improve anaemia and red blood cell health in people with sickle cell disease.
The BioInnovation Institute of Denmark, a non-profit foundation, has added three new start-up companies to its portfolio of enterprises that it believes will significantly contribute to the development of new medicines and health technologies in Europe. The companies are Sevenless Therapeutics Ltd of the UK; Veil.ai Oy of Finland; and Myopax GmbH of Germany.
An enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD), a rare genetic disease that can cause premature death, has cleared the US Food and Drug Administration making it the first medicine to treat symptoms of the disease that are not related to the central nervous system. The FDA approval of Xenpozyme (olipudase alfa) was granted to Genzyme, a division of Sanofi SA.
The US Food and Drug Administration has approved two new bivalent vaccines to protect against Covid-19. They are to be administered as an updated single booster dose at least two months after primary or booster vaccination. The decisions were taken in response to the prevalence of the omicron variant of the SARS-CoV-2 virus and specifically to its two new subvariants BA.4 and BA.5.
The Bill & Melinda Gates Foundation has invested $5 million in a Danish company that is developing a new type of biologic to strengthen the gut microbiome and overcome resistance to antibiotics. In a statement on 30 August, Bactolife A/S said its technology is designed to reduce the risk of bacterial infections in both humans and animals. Novo Seeds, a unit of Novo Holdings A/S, led a €7 million seed financing round for Bactolife in April 2021.
Finland-based Kaiku Health Oy and Novartis have expanded their partnership in digital medicine in order to use machine learning to predict symptoms of multiple diseases. The two companies have been collaborating since June 2021 on a project involving the monitoring of patients with melanoma. Using Kaiku’s digital platform, data is collected from cancer patients and then fed back to healthcare workers to help them personalise care. Patients participating in the first project had melanoma and were receiving combination therapies which inhibit the BRAF and MEK proteins.
A spin-out of the Belgian university KU Leuven (Katholieke Universiteit Leuven) has raised €30 million from a large group of venture capitalists in order to develop a new generation of vaccines. AstriVax NV will use the seed funding to bring a thermostable yellow fever vaccine into clinical development and further develop candidate vaccines for rabies and chronic hepatitis B.
Novartis is to spin off Sandoz, its generics business, into a separately incorporated Swiss company by the second half of 2023 in order to focus on proprietary medicine development. The decision, announced on 25 August, follows a year-long strategic review that included the options of retaining Sandoz as an autonomous business unit within the group, or divesting it.